ライフサイエンスコーパス: ARB

1 ARB inhibited EBOV Zaire Kikwit infection when added bef

2 ARB inhibited HHV-8 replication to a similar degree as c

3 ARB is currently used clinically in several countries bu

4 085 participants with CKD, 34.9% used an ACE/ARB.

5 We examined ACE/ARB trends from 1999 to 2014 among 38,885 adult National

6 ex-, and race/ethnicity-adjusted models, ACE/ARB use was significantly associated with era (adjusted

7 Rates of ACE/ARB use increased in the early 2000s among United States

8 associated with lower IOP and systemic ACEI, ARB, statin, and sulfonylurea use was associated with hi

9 ta-analysis showed that treatment with ACEI, ARB, BB, MRA, and ARNI and their combinations were bette

10 ACEI/ARB administration was associated with a significantly l

11 ACEI/ARB therapy had a significant negative effect on the DST

12 ACEI/ARB use was defined as prescription fillings 6 months pr

13 ACEI/ARB use was independently associated with acute kidney i

14 ACEI/ARB use was independently associated with the following

15 SE]: 2.7%), statin in 33.1% (SE: 2.4%), ACEI/ARB in 28.4% (SE: 2.0%), and cilostazol in 4.7% (SE: 1.0

16 statins (OR: 2.6; 95% CI: 1.8 to 3.9), ACEI/ARB (OR: 2.6; 95% CI: 1.8 to 3.9), and smoking cessation

17 rted therapy with a statin, 11% with an ACEI/ARB, and 5% with both.

18 ntly different between non-ACEi/ARB and ACEi/ARB groups.

19 ties, vital signs, laboratory data, and ACEi/ARB usage were analyzed.

20 Combined BB and ACEI/ARB use was associated with the lowest incidence of MACE

21 Combined BB and ACEI/ARB was associated with the lowest incidence of all-caus

22 ged with revascularization, both BB and ACEI/ARB were associated with a lower incidence of 12-month a

23 The association between ACEI/ARB treatment and outcomes (mortality, myocardial infarc

24 ving target doses of MRA, beta-blocker, ACEI/ARB, and ARNI therapy, respectively.

25 hibitors/angiotensin receptor blockers (ACEI/ARB) in acute myocardial infarction (AMI) were largely c

26 ssessed the association between chronic ACEI/ARB use and the occurrence of kidney, lung, heart, and l

27 These findings suggest that continued ACEi/ARB use in hypertensive COVID-19 patients yields better

28 5% used ACEI/ARBs vs 85.4% of controls; ACEI/ARB use compared with other antihypertensive drugs was n

29 ) compared to patients who discontinued ACEi/ARB.

30 te outcome of AKI and mortality favored ACEI/ARB treatment.

31 % for MRA, 10% for beta-blocker, 7% for ACEI/ARB, and 10% for ARNI; corresponding proportions with di

32 not significantly different between non-ACEi/ARB and ACEi/ARB groups.

33 dings do not support discontinuation of ACEI/ARB medications that are clinically indicated in the con

34 he 3-year mortality was 19.8% (17.4% of ACEI/ARB users and 25.4% of nonusers).

35 or severe COVID-19 occurred in 31.9% of ACEI/ARB users vs 14.2% of nonusers by 30 days (adjusted HR,

36 The daily dose of ACEI/ARB was independently associated with altered kidney mar

37 ltaneously treated with target doses of ACEI/ARB/ARNI, beta-blocker, and MRA.

38 charge and continuous follow-up data on ACEI/ARB use among AMI survivors (2006 to 2009) included in a

39 ind consistent evidence that statins or ACEI/ARB have an effect on global neurocognitive function.

40 stimated the causal effect of statin or ACEI/ARB initiation on neurocognitive function; initial const

41 e seen in single domains with statin or ACEI/ARB therapy, we did not find consistent evidence that st

42 participants not receiving a statin or ACEI/ARB within 30 days of first neurologic assessment (basel

43 lants analyzed, 15,250 (38.9%) received ACEI/ARB and 24,001 (61.1%) received other antihypertensive t

44 sociation class I guideline-recommended ACEI/ARB therapy, and the use varies by patient factors.

45 In the ACEI/ARB group, 18.1% died within 30 days vs 7.3% in the nonu

46 his study sought to investigate whether ACEI/ARB treatment after AMI is associated with better outcom

47 Yet the extent to which ACEI/ARB therapy is applied in patients with acute coronary s

48 usted HR 0.69, 95% CI 0.55-0.88), while ACEI/ARB was significantly associated with lower all-cause mo

49 was observed for patients treated with ACEI/ARB (3-year hazard ratio: 0.80; 95% confidence interval:

50 Treatment with ACEI/ARB after AMI was associated with improved long-term sur

51 Overall, those treated with ACEI/ARB also had lower 3-year risk for myocardial infarction

52 ories but was significantly higher with ACEI/ARB treatment.

53 nts, the increase in UN associated with ACEI/ARB use could predict the development of acute respirato

54 Patients chronically treated with ACEI/ARB who have severe COVID-19 are at increased risk of ac

55 45,697 patients (71%) were treated with ACEI/ARB.

56 he study 30% (44/149) were treated with ACEI/ARB.

57 However, patients who continued ACEi/ARBs in the hospital had a markedly lower ICU admission

58 s only, 0.98 (95% CI: 0.91 to 1.07) for ACEI/ARBs and statins only, 1.17 (95% CI: 1.10 to 1.25) beta-

59 There were 895 users (20.0%) of ACEI/ARBs and 3585 nonusers (80.0%).

60 examine the association between use of ACEI/ARBs vs other antihypertensive drugs and the incidence r

61 Prior use of ACEI/ARBs was not significantly associated with COVID-19 diag

62 Among those with COVID-19, 86.5% used ACEI/ARBs vs 85.4% of controls; ACEI/ARB use compared with ot

63 xample, inhalational administration of ACEIs/ARBs (to deliver drugs directly to the lungs) and use of

64 However, treatment of COVID-19 with ACEIs/ARBs poses several challenges.

65 t target the generation (ACEIs) and actions (ARBs) of Ang II.

66 These tumor microenvironment-activated ARBs (TMA-ARBs) remain intact and inactive in circulatio

67 obing (Raman-DIP) to detect metabolic active ARB (MA-ARB) in situ at the single-cell level in human g

68 in tumors, wherein they break down to active ARBs.

69 d the foulant layer synergistically affected ARB removal, but the foulant layer was the main factor t

70 odds ratio 0.62, 95% CI 0.43-0.90) and after ARB monotherapy (0.77, 0.65-0.92).

71 I type 1 receptors (AT1R, encoded by AGTR1) (ARBs or sartans) are strongly neuroprotective, neurorest

72 All ARBs were found to be potent inhibitors of G protein act

73 , the combination of an ACE inhibitor and an ARB failed to provide significant benefits on major outc

74 The addition of an ARB did not alter the decline in the estimated GFR.

75 giotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maxima

76 d with lower doses, higher doses of ACEI and ARB significantly though modestly improved the composite

77 ospective cohort studies found that ACEI and ARB use was not associated with a higher likelihood of r

78 ithout ARB (F0), with ARB 5 g/100 g (F5) and ARB 10 g/100 g (F10) presented 4.23%, 2.83% and 0.11% fa

79 injury, although combined ACE inhibitor and ARB treatment had the lowest rank among all intervention

80 Any benefits of combined ACE inhibitor and ARB treatment need to be balanced against potential harm

81 y, with the exception of ARB monotherapy and ARB plus ACEI.

82 o investigate the effect of dose of ACEI and ARBs on outcomes and drug discontinuation in patients wi

83 randomized trials plan to evaluate ACEIs and ARBs for treatment of COVID-19.

84 We also discuss why and how ACEIs and ARBs provide cardiovascular, renal and also pulmonary pr

85 showed similar effects of ACE inhibitors and ARBs on major cardiovascular and renal outcomes.

86 The use of ACE inhibitors and ARBs was more common among case patients than among cont

87 n-based study, the use of ACE inhibitors and ARBs was more frequent among patients with Covid-19 than

88 ences were showed between ACE inhibitors and ARBs with respect to all-cause mortality, cardiovascular

89 ACE inhibitors and ARBs, alone or in combination, were the most effective s

90 Arbidol (ARB) is a synthetic antiviral originally developed to co

91 The antiviral drug arbidol (ARB), already in clinical use in several countries as an

92 taining multiple bacterial types (e.g., ASB, ARB); and (3) predict if illness is treatable with antib

93 from more than 250 tests and 34 vehicles at ARB's Haagen-Smit Laboratory (HSL).

94 The antibiotic-resistant bacteria (ARB) and antibiotic-resistant genes (ARGs) in human gut

95 olonized with antibiotic-resistant bacteria (ARB) are prone to systemic infections that are difficult

96 ification for antibiotic-resistant bacteria (ARB) has been hindered by the absence of suitable DRMs f

97 tion of these antibiotic-resistant bacteria (ARB) is fuelled by antibiotic selection pressure, inter-

98 emoving three antibiotic-resistant bacteria (ARB), namely, blaNDM-1-positive Escherichia coli PI-7, b

99 rs, acetogens, and anode-respiring bacteria (ARB).

100 iver discharge in the Athabasca River Basin (ARB) with (i) a generalized least-squares (GLS) regressi

101 ur results suggest a strong relation between ARB in human gut microbiota and personal medical history

102 ckdown of AT1 and inhibited by AT1 blockade (ARB).

103 ) inhibitor or angiotensin receptor blocker (ARB) affected the results.

104 atment with an angiotensin-receptor blocker (ARB) and an angiotensin-converting-enzyme (ACE) inhibito

105 ACE inhibitor/angiotensin receptor blocker (ARB) in LV dysfunction (64.1% vs. 56.3%; aPR: 1.11; 95%

106 itor (ACEI) or angiotensin receptor blocker (ARB) influences disease outcomes.

107 ctivity to the angiotensin receptor blocker (ARB) losartan.

108 o characterize angiotensin receptor blocker (ARB) prescription trends to evaluate whether recalls of

109 tor (ACEI) and angiotensin receptor blocker (ARB) should be used for secondary prevention in all or i

110 hibitor (ACEI)/angiotensin receptor blocker (ARB) use and mortality in patients with chronic kidney d

111 itor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin receptor-neprilysin inhibitor (ARNI),

112 tan [an angiotensin type 1 receptor blocker (ARB)] ameliorated colitis in wild-type mice, confirming

113 ors (ACEI) or angiotensin receptor blockers (ARB) are generally well tolerated, the impact of these t

114 rs (ACEI) and angiotensin receptor blockers (ARB) doses on outcomes in patients with heart failure (H

115 (ACEi) or angiotensin II receptor blockers (ARB) during hospitalization of 614 hypertensive laborato

116 ors (ACEI) or angiotensin receptor blockers (ARB) initiated after myocardial infarction (MI) reduce m

117 inhibitors or angiotensin receptor blockers (ARB) were associated with lower risk of major gastrointe

118 itors (ACEI), angiotensin receptor blockers (ARB), beta-blockers (BB), mineralocorticoid receptor ant

119 inhibitors/angiotensin II receptor blockers (ARB), beta-blockers and statins are recommended after ac

120 ors (ACEI) or angiotensin receptor blockers (ARB).

121 AT1R blockers (ARBs) have been widely used in clinical settings as anti

122 iotensin II type 1 receptor (AT1R) blockers (ARBs) are among the most prescribed drugs.

123 rugs have been developed as AT(1)R blockers (ARBs), the structural basis for AT(1)R ligand-binding an

124 en the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors

125 inhibitors or angiotensin receptor blockers (ARBs) and beta blockers.

126 s (ACE-Is) or angiotensin receptor blockers (ARBs) both increased significantly (37% versus 82%, RR 2

127 Angiotensin receptor blockers (ARBs) convert myofibroblast CAFs to a quiescent state, b

128 The use of angiotensin receptor blockers (ARBs) correlates with reduced onset and progression of A

129 (ACEI) or angiotensin II receptor blockers (ARBs) does not increase susceptibility to SARS-CoV-2 inf

130 ibitors or angiotensin II receptor blockers (ARBs) in CKD is lacking.

131 s (ACEIs) and angiotensin-receptor blockers (ARBs) in coronavirus disease 2019 (COVID-19) susceptibil

132 inhibitors or angiotensin receptor blockers (ARBs) in patients with type 2 diabetes and chronic kidne

133 nhibitors and angiotensin-receptor blockers (ARBs) in this clinical context.

134 rs (ACEIs) or angiotensin receptor blockers (ARBs) may be beneficial in COVID-19.

135 s (ACEis) and angiotensin receptor blockers (ARBs) may increase the risk of hyperkalemia (serum potas

136 itors (ACEIs)/angiotensin receptor blockers (ARBs) may make patients more susceptible to coronavirus

137 inhibitors or angiotensin-receptor blockers (ARBs), and beta blockers are similar for men and women w

138 ) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors.

139 ) inhibitors, angiotensin-receptor blockers (ARBs), beta blockers, and aldosterone antagonists in adu

140 ) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, and mineralocorticoid receptor ant

141 anaphylaxis, angiotensin-receptor blockers (ARBs), beta-adrenergic blockers, epinephrine, and Kounis

142 stem, such as angiotensin receptor blockers (ARBs), have been associated with lower incidence and pro

143 (ACE-Is) and angiotensin receptor blockers (ARBs), may be associated with decreased PTSD symptoms.

144 inhibitors or angiotensin receptor blockers (ARBs).

145 tors [ACEIs], angiotensin receptor blockers [ARBs], and beta-blockers adjusted for blood pressure, st

146 rs [ACEIs] or angiotensin receptor blockers [ARBs], and cilostazol) and lifestyle counseling (exercis

147 gonist drugs (angiotensin receptor blockers, ARBs, or sartans) at preventing activation of these two

148 The California Air Resources Board (ARB) adopted the low emission vehicle (LEV) III particul

149 The California Air Resources Board (ARB) and the City of Sacramento undertook this study to

150 g from mouse thoracic aorta was abolished by ARB or genetic deletion of AT1.

151 pand the list of viruses that are blocked by ARB in a laboratory setting to include Ebola virus, Taca

152 nd the list of viruses that are inhibited by ARB and demonstrate that ARB suppresses in vitro infecti

153 otein showed that infection was inhibited by ARB at early stages, most likely at the level of viral e

154 ssion of hepatitis B virus and poliovirus by ARB.

155 new framework to quantify the risk posed by ARB and antibiotics.

156 E-I/ARB effect on PTSD may be driven more by ARBs (e.g., Losartan) than by ACE-Is.

157 ew approach to DRMs is introduced to capture ARB and antibiotic-susceptible bacteria (ASB) dynamics a

158 ith activity against some of the most common ARB have been developed, but resistance to these agents

159 rticipants, 15/20 (75%) experienced complete ARB decolonization.

160 The primary endpoint was complete ARB decolonization at 1 month after FMT.

161 effects on antitumor immunity, we developed ARB nanoconjugates that preferentially accumulate and ac

162 ific interactions between AT1R and different ARBs, including olmesartan derivatives with inverse agon

163 oborating a common binding mode of different ARBs.

164 Each of the eight ARBs was then docked, using ARB-optimized parameters, to

165 splantation (FMT) could be used to eradicate ARB in humans.

166 d the best, followed by ANN, SMM and finally ARB.

167 hindered by the absence of suitable DRMs for ARB.

168 confidence interval {CI}, 0.86 to 1.05] for ARBs and 0.96 [95% CI, 0.87 to 1.07] for ACE inhibitors)

169 odds ratio, 0.83 [95% CI, 0.63 to 1.10] for ARBs and 0.91 [95% CI, 0.69 to 1.21] for ACE inhibitors)

170 The mechanism depicting how ARBs such as losartan restore cerebrovascular and cognit

171 However, ARB effectiveness varies widely, which may be due to non

172 ug classes, results indicated that the ACE-I/ARB effect on PTSD may be driven more by ARBs (e.g., Los

173 stly replicated the overall effects of ACE-I/ARB medication associated with lower rate of PTSD diagno

174 here we tested whether the effects of ACE-I/ARB status on PTSD differ by sex.

175 tom Scale (M-PSS) was administered and ACE-I/ARB status was determined by self-report.

176 In ARB patients, peripapillary sparing is a consistent feat

177 -frequency variability must be considered in ARB water allocation, which has not been the case.

178 st 3 months of treatment with ACE inhibitor, ARB, beta blocker, or aldosterone antagonist.

179 perative lisinopril-equivalent ACE inhibitor/ARB dose was >5 mg, the risk of major GIB decreased in a

180 ACE inhibitor/ARB dose was abstracted from medical records.

181 ACE inhibitor/ARB exposure status was landmarked at 30 days post-opera

182 ACE inhibitor/ARB therapy is associated with a protective effect of de

183 models assessed the impact of ACE inhibitor/ARB therapy on major GIB and AVM-related GIB, whereas st

184 Patients who received an ACE inhibitor/ARB within 30 days post-operatively had a 57% reduction

185 to elucidate the efficacy of ACE inhibitors, ARBs, beta blockers, and aldosterone antagonists in pati

186 t 3 months of treatment with ACE inhibitors, ARBs, or aldosterone antagonists, there was no statistic

187 o 1.21) for being adherent to ACE inhibitors/ARBs and beta-blockers only, 0.98 (95% CI: 0.91 to 1.07)

188 Patients adherent to ACE inhibitors/ARBs and statins only had similar mortality rates as tho

189 Nonadherence to ACE inhibitors/ARBs and/or statins was associated with higher mortality

190 19 (95% CI: 1.07 to 1.32) for ACE inhibitors/ARBs only, 1.32 (95% CI: 1.21 to 1.44) for beta-blockers

191 of tradeoffs in adherence to ACE inhibitors/ARBs, beta-blockers, and statins on survival among older

192 age who had prescriptions for ACE inhibitors/ARBs, beta-blockers, and statins, and survived >/=180 da

193 were adherent to statins and ACE inhibitors/ARBs.

194 Among individuals treated with ACE-Is/ARBs in the initial sample, women had significantly high

195 polymer from Agrobacterium radiobacter k84 (ARB) were characterised during 60days of frozen storage.

196 id-degradable polymers and chemically linked ARBs to the polymer most sensitive to tumor pH.

197 aman-DIP) to detect metabolic active ARB (MA-ARB) in situ at the single-cell level in human gut micro

198 We analysed the relative abundances of MA-ARB under different concentrations of amoxicillin, cepha

199 ated cell sorting (RACS) was used to sort MA-ARB from human gut microbiota, and mini-metagenomic DNA

200 The sorted MA-ARB and their associated ARGs were identified.

201 k between phenotypes and genotypes of the MA-ARB, Raman-activated cell sorting (RACS) was used to sor

202 Moreover, ARB doses are limited by systemic adverse effects such a

203 roaden the spectrum of antiviral efficacy of ARB to include globally prevalent viruses that cause sig

204 t be familiar with the local epidemiology of ARB, remain vigilant for the emergence of novel resistan

205 isorders is safe and promotes eradication of ARB from the gastrointestinal tract.

206 g all-cause mortality, with the exception of ARB monotherapy and ARB plus ACEI.

207 to unravel both phenotypes and genotypes of ARB in human gut microbiota at the single-cell level.

208 d chicken flavour decreased with increase of ARB; no difference was found for tenderness among the fo

209 ogressed to subcritical fouling, the LRVs of ARB decreased at increasing operating transmembrane pres

210 o increase the accuracy of the prediction of ARB resistance in order to increase overall ARB effectiv

211 zed by a median of 2 (range, 1-4) strains of ARB.

212 practices proven to prevent transmission of ARB and other pathogens.

213 layer could remove more than 5 log units of ARB.

214 rmacological insights into the drug class of ARBs and medicinal chemistry insights for future drug de

215 ty enhances the CAF-reprogramming effects of ARBs while eliminating blood pressure-lowering effects.

216 iption trends to evaluate whether recalls of ARBs prompted by discovery of potentially carcinogenic i

217 , most nsSNPs drastically alter a sub-set of ARBs affinity to the AT1R.

218 To enhance the efficacy and specificity of ARBs in cancer with the goal of revealing their effects

219 o, 0.33; 95% CI, 0.20 to 0.54) or the use of ARBs (6.8% vs. 5.7%; odds ratio, 1.23; 95% CI, 0.87 to 1

220 Use of ARBs or ACE inhibitors did not show any association with

221 rcinogenic impurities shifted utilization of ARBs individually and as a drug class.

222 with inflammatory bowel disease who were on ARB therapy compared to patients not receiving ARB thera

223 d trials that compared high doses of ACEI or ARB against low doses among patients with HF with reduce

224 outpatient HF encounter, and (3) >=1 ACEI or ARB fill, all within 1-year preindex.

225 n sacubitril/valsartan switchers and ACEI or ARB maintainers.

226 monotherapy is more efficacious than ACEI or ARB monotherapy.

227 addition of eplerenone to background ACEI or ARB therapy attenuates the progressive decline in left v

228 igh-certainty evidence suggests that ACEI or ARB use is not associated with more severe COVID-19 dise

229 bitril/valsartan and if none, for an ACEI or ARB.

230 il/valsartan versus maintained on an ACEI or ARB.

231 ormal renal function treated with an ACEi or ARB.

232 ion despite treatment with either an ACEi or ARB.

233 renal function and are receiving ACEi and/or ARB therapy.

234 e combined dose of beta blocker and ACE-I or ARB: +6% [+2%, +10%]).

235 c HF) and treatment with an ACE inhibitor or ARB (i.e., ACE inhibitor or ARB-yes vs. ACE inhibitor or

236 ersus conventional therapy (ACE inhibitor or ARB and beta blocker) in patients with chronic HFrEF by

237 p of the EMPHASIS-HF trial (ACE inhibitor or ARB and beta blocker).

238 r HF history (p = 0.350) or ACE inhibitor or ARB treatment (p = 0.880) and the effect of S/V versus e

239 e of previous HF history or ACE inhibitor or ARB treatment.

240 table cardiac defibrillator+ACE inhibitor or ARB+BB+mineralocorticoid receptor antagonist, implantabl

241 table cardiac defibrillator+ACE inhibitor or ARB+BB, and angiotensin receptor-neprilysin inhibitor+BB

242 ts had been treated with an ACE inhibitor or ARB, while 458 (52%) had not been treated with an ACE in

243 CE inhibitor or ARB-yes vs. ACE inhibitor or ARB-no) at admission.

244 ACE inhibitor or ARB (i.e., ACE inhibitor or ARB-yes vs. ACE inhibitor or ARB-no) at admission.

245 ad not been treated with an ACE inhibitor or ARB.

246 (angiotensin-converting enzyme inhibitor) or ARB (angiotensin II receptor blocker), be switched to sa

247 Compared with low dose, high-dose ACEI or ARBs decreased all-cause mortality modestly (relative ri

248 ecommended target doses of ACE inhibitors or ARBs (99 [25%] vs 304 [23%], p=0.61) and beta blockers (

249 angiotensin-converting enzyme) inhibitors or ARBs (angiotensin receptor blockers) with beta-blockers

250 there was no evidence that ACE inhibitors or ARBs affected the risk of COVID-19.

251 ces in the optimal dose of ACE inhibitors or ARBs and beta blockers in patients with HFrEF.

252 might need lower doses of ACE inhibitors or ARBs and beta blockers than men, and brings into questio

253 iation and up-titration of ACE inhibitors or ARBs and beta blockers was encouraged by protocol.

254 of the recommended dose of ACE inhibitors or ARBs and beta blockers, but women showed approximately 3

255 rns were observed for both ACE inhibitors or ARBs and beta blockers, with women having approximately

256 recommend substitution of ACE inhibitors or ARBs with ARNIs in appropriate patients.

257 ial harmful association of ACE inhibitors or ARBs with in-hospital death in this clinical context.

258 antidiabetic treatment and ACE inhibitors or ARBs, for at least 8 weeks before study entry.

259 r placebo as an adjunct to ACE inhibitors or ARBs.

260 o standard care, including ACE inhibitors or ARBs.

261 guideline recommendations (42% for ACE-Is or ARBs, 29% for beta blockers in 2014) and was largely unc

262 reduction in major cardiovascular outcomes: ARB (odds ratio [OR] 1.02; 95% credible interval [CrI] 0

263 ARB resistance in order to increase overall ARB effectiveness.

264 e were no severe adverse events, and partial ARB decolonization was observed in 20/25 (80%) of the FM

265 oints included safety assessment and partial ARB decolonization.

266 ng in silico approaches towards personalized ARB therapy.

267 1.10; 95% CrI 0.90-1.40), ACE inhibitor plus ARB (0.97; 95% CrI 0.72-1.29), DR inhibitor plus ACE inh

268 nterval [CrI] 0.90-1.18), ACE inhibitor plus ARB (0.97; 95% CrI 0.79-1.19), DR inhibitor plus ACE inh

269 2; 95% CrI 0.96-1.81), and DR inhibitor plus ARB (1.00; 95% CrI 0.73-1.38).

270 9; 95% CrI 0.65-1.57), and DR inhibitor plus ARB (1.18; 95% CrI 0.78-1.84).

271 ithin N298 -L314 strongly effected predicted ARB affinity, which aligns with early mutagenesis studie

272 ar rescue of losartan, a commonly prescribed ARB, in a mouse model of AD.

273 caribe arenavirus, and HHV-8, and we propose ARB as a broad-spectrum antiviral drug that may be usefu

274 B therapy compared to patients not receiving ARB therapy.

275 nsSNPs may abrogate the binding of selective ARBs.

276 ccine administrator, and study statistician (ARB) were unmasked.

277 These results suggest ARB as a promising fat substitute, capable of maintain t

278 at are inhibited by ARB and demonstrate that ARB suppresses in vitro infection of mammalian cells wit

279 We have previously shown that ARB inhibits in vitro hepatitis C virus (HCV) by blockin

280 e surface attributed the removal of both the ARB and ARGs to adsorption, which was facilitated by an

281 ows long-term declining flows throughout the ARB.

282 hibitor and each of the remaining therapies: ARB (OR 1.10; 95% CrI 0.90-1.40), ACE inhibitor plus ARB

283 These ARB include methicillin-resistant Staphylococcus aureus,

284 e tumor microenvironment-activated ARBs (TMA-ARBs) remain intact and inactive in circulation while ac

285 Notably, TMA-ARBs alleviate immunosuppression and improve T lymphocyt

286 :1; block size of six [Malian] or four [US]; ARB produced computer-generated randomisation lists; cli

287 Docking simulations of the clinically used ARBs into the AT(1)R structure further elucidated both t

288 ach of the eight ARBs was then docked, using ARB-optimized parameters, to each polymorphic AT1R (n =

289 blast CAFs to a quiescent state, but whether ARBs can reprogram CAFs to promote T lymphocyte activity

290 However, the manner by which ARBs mediate their beneficial effects is unknown.

291 AGON-HF (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fracti

292 (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fracti

293 F trial (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fracti

294 d in the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejecti

295 Participants colonized with ARB were treated with intraduodenal FMT according to a p

296 cooking, formulations without ARB (F0), with ARB 5 g/100 g (F5) and ARB 10 g/100 g (F10) presented 4.

297 est rates of colonization and infection with ARB worldwide.

298 iotensin Receptor-Neprilysin Inhibitor] with ARB [Angiotensin Receptor Blocker] Global Outcomes in HF

299 Although patients with ARB are presumed to have no functioning bestrophin chann

300 After cooking, formulations without ARB (F0), with ARB 5 g/100 g (F5) and ARB 10 g/100 g (F1